Literature DB >> 6963363

[Adjuvant chemotherapy of malignant bone tumors].

W Wilmanns, H Sauer, A Schalhorn.   

Abstract

The interdisciplinary approach in the combined modality treatment of non-metastasized osteogenic sarcoma follows now well-established guidelines: (1) diagnostic biopsy; (2) pretherapeutic cytostatic polychemotherapy (cyclic administration of adriamycin, high-dose methotrexate or cis-platinum, BCD = bleomycin + cyclophosphamide + dactinomycin); (3) limb-saving oncological radical operation with histological evaluation of the effectiveness of the preoperative chemotherapy; (4) continuation of the preoperative chemotherapy as postoperative adjuvant chemotherapy. This interdisciplinary approach in the treatment of localized osteogenic sarcoma has improved the 5-year survival rate from 20% to 80%.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6963363     DOI: 10.1007/BF01271823

Source DB:  PubMed          Journal:  Langenbecks Arch Chir        ISSN: 0023-8236


  8 in total

1.  Chemotherapy and thoractomy for metastatic osteogenic sarcoma. A model for adjuvant chemotherapy and the rationale for the timing of thoracic surgery.

Authors:  G Rosen; A G Huvos; C Mosende; E J Beattie; P R Exelby; B Capparos; R C Marcove
Journal:  Cancer       Date:  1978-03       Impact factor: 6.860

2.  Osteogenic sarcoma under the age of twenty-one. A review of one hundred and forty-five operative cases.

Authors:  R C Marcove; V Miké; J V Hajek; A G Levin; R V Hutter
Journal:  J Bone Joint Surg Am       Date:  1970-04       Impact factor: 5.284

3.  The biochemistry of the citrovorum factor rescue effect in normal bone marrow cells after high-dose methotrexate.

Authors:  H Sauer; A Schalhorn; W Wilmanns
Journal:  Eur J Cancer       Date:  1979-10       Impact factor: 9.162

4.  [Osteosarcoma 1978 a turning point in prognosis through adjuvant chemotherapy following adequate surgery (author's transl)].

Authors:  R Kotz
Journal:  Wien Klin Wochenschr Suppl       Date:  1978

5.  Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy.

Authors:  G Rosen; B Caparros; A G Huvos; C Kosloff; A Nirenberg; A Cacavio; R C Marcove; J M Lane; B Mehta; C Urban
Journal:  Cancer       Date:  1982-03-15       Impact factor: 6.860

6.  Primary osteosarcoma of bone. Clinicopathologic investigation of 243 cases, with necropsy studies in 54.

Authors:  G Uribe-Botero; W O Russell; W W Sutow; R G Martin
Journal:  Am J Clin Pathol       Date:  1977-05       Impact factor: 2.493

7.  [Detection of methotrexate in human serum. Comparison between an enzymatic and an enzyme-immunologic method].

Authors:  A Schalhorn; W Wilmanns
Journal:  Onkologie       Date:  1980-08

8.  [Radiational basis and practice of the citrovorum factor (Leucovorin) protection after high-dose methotrexate therapy. High-dose methotrexate/leucovorin].

Authors:  H Sauer; A Schalhorn
Journal:  Onkologie       Date:  1980-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.